Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

Revolade (2012)

Αναφορές

Βιβλιογραφική αναφορά

Στοιχεία εκδότη

Εκδότης :
GlaxoSmithKline UK
Διεύθυνση :
Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Name of the medicinal product

Revolade 25 mg and 50 mg film-coated tablets.

Qualitative and quantitative composition

Each film-coated tablet contains eltrombopag olamine equivalent to 25 mg or 50 mg eltrombopag. Excipients: For the full list of excipients, see section 6.1.

Pharmaceutical form

Film-coated tablet. 25 mg: Round, biconvex, white film-coated tablet debossed with GS NX3 and 25 on one side. 50 mg: Round, biconvex, brown film-coated tablet debossed with GS UFU and 50 on one side. ...

Therapeutic indications

Revolade is indicated for adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Revolade ...

Posology and method of administration

Eltrombopag treatment should remain under the supervision of a physician who is experienced in the treatment of haematological diseases. Eltrombopag dosing requirements must be individualised based on ...

Contraindications

Hypersensitivity to eltrombopag or to any of the excipients listed in section 6.1.

Special warnings and precautions for use

Risk of hepatotoxicity Eltrombopag administration can cause abnormal liver function. In clinical studies with eltrombopag, increases in serum alanine aminotransferase (ALT), aspartate aminotransferase ...

Interaction with other medicinal products and other forms of interaction

Effects of eltrombopag on other medicinal products HMG CoA reductase inhibitors In vitro studies demonstrated that eltrombopag is not a substrate for the organic anion transporter polypeptide, OATP1B1, ...

Fertility, pregnancy and lactation

Pregnancy There are no or limited amount of data from the use of eltrombopag in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. ...

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

Undesirable effects

Based on an analysis of all chronic ITP patients receiving eltrombopag in 3 controlled and 2 uncontrolled clinical studies, the overall incidence of adverse events in subjects treated with eltrombopag ...

Overdose

In the event of overdose, platelet counts may increase excessively and result in thrombotic/thromboembolic complications. In case of an overdose, consider oral administration of a metal cation-containing ...

Pharmacodynamic properties

Pharmacotherapeutic group: Antihemorrhagics ATC code: B02BX05 Mechanism of action TPO is the main cytokine involved in regulation of megakaryopoiesis and platelet production, and is the endogenous ligand ...

Pharmacokinetic properties

Pharmacokinetics The plasma eltrombopag concentration-time data collected in 88 subjects with ITP in Studies TRA100773A and TRA100773B were combined with data from 111 healthy adult subjects in a population ...

Preclinical safety data

Eltrombopag does not stimulate platelet production in mice, rats or dogs because of unique TPO receptor specificity. Therefore, data from these animals do not fully model potential adverse effects related ...

List of excipients

Tablet core (25 mg and 50 mg): Magnesium stearate Mannitol (E421) Microcrystalline cellulose Povidone (K30) Sodium starch glycolate Type A Tablet coating (25 mg): Hypromellose Macrogol 400 Polysorbate ...

Incompatibilities

Not applicable.

Shelf life

4 years.

Special precautions for storage

This medicinal product does not require any special storage conditions.

Nature and contents of container

Aluminum blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. Not all pack sizes may be marketed.

Special precautions for disposal and other handling

Any unused product or waste material should be disposed of in accordance with local requirements.

Marketing authorization holder

GlaxoSmithKline Trading Services Limited 6900 Cork Airport Business Park Kinsale Road Cork Ireland

Marketing authorization number(s)

25 mg (14 tablets): EU/1/10/612/001 25 mg (28 tablets): EU/1/10/612/002 25 mg (84 tablets): EU/1/10/612/003 50 mg (14 tablets): EU/1/10/612/004 50 mg (28 tablets): EU/1/10/612/005 50 mg (84 tablets): EU/1/10/612/006 ...

Date of first authorization / renewal of the authorization

Date of first authorisation: 11 March 2010

Date of revision of the text

27 June 2012
Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.